Kadmon’s Rezurock scores surprise FDA nod in chronic graft-versus-host-disease
With a surprise FDA approval Friday afternoon, Kadmon Holdings is on its way to becoming a commercial drugmaker. The FDA cleared Kadmon’s Rezurock to treat chronic graft-versus-host disease, a serious complication of transplant procedures. Formerly known as belumodsil, the drug is a first-in-class ROCK2 inhibitor—and now Kadmon’s first approved drug. GVHD occurs when donor cells mount an immune response against a patient’s own tissues and organs. While doctors can… Read More »
